Roivant Sciences Stock Performance

ROIV Stock  USD 28.28  -0.54  -1.87%   
Roivant Sciences' total-return profile spans short-term moves to multi-year compounding. Based on the 3 months horizon, Roivant Sciences shows an expected return of 0.17%.
Risk-Adjusted Performance
0High
6 · Contained
Roivant Sciences currently ranks below 6% of comparable global equities and portfolios when recent risk-adjusted returns are measured across a 90-day horizon. At large-cap scale, institutional coverage and secondary-market liquidity are typically well established. Roivant Sciences is showing early signs of positive return efficiency on a risk-adjusted basis. Learn More

Relative Risk vs. Return Landscape

If you had invested $ 2,582 in Roivant Sciences on February 6, 2026 and sold it today, you would have earned $ 246.00 , a return of 9.53% over 90 days. Roivant Sciences is currently generating a 0.1678% daily expected return and carries 2.18% risk (volatility on return distribution) over a 90-day horizon. In relative terms, Roivant Sciences exhibits above-average volatility, exceeding roughly 81% of comparable stocks, and ROIV has trailed 97% of traded instruments in return over the 90-day horizon.
  Expected Return   
       Risk  
This comparison focuses on expected return, realized volatility, and risk efficiency versus the market. It highlights whether the current reward profile compensates for the level of uncertainty assumed. Given a 90-day horizon, ROIV generates 2.36 times more return on investment than the market. However, ROIV is 2.36 times more volatile than its market benchmark. Its risk-adjusted efficiency stands at about 0.08% per unit of risk. Dow Jones Industrial is currently generating roughly -0.01% per unit of risk.

Target Price Odds to finish over Current Price

For Roivant Sciences Stock, the tendency of price to converge toward a long-term average provides a useful forecasting baseline. Investors have relied on this tendency for decades, though persistent mispricings in some instruments suggest additional risk factors. Certain stocks show persistent deviations from their intrinsic value estimates, typically explained by the risk investors bear. Applying mean reversion analysis to Roivant Sciences Stock helps identify potential entry points when prices are extended.
Current PriceHorizonTarget PriceOdds moving above the current price in 90 days
28.28 90 days 28.28
about 42.51 %
Based on standard probability analysis, the odds of Roivant Sciences moving above the current price in 90 days from now are about 42.51 %. Over this horizon, the return distribution for this stock has leaned toward above-current outcomes historically. (The curve highlights the price band where the market has recently concentrated expectations for Roivant Sciences Stock over the next 90 days). A narrower shape indicates the market has recently priced Roivant Sciences Stock into a more concentrated outcome range.
Given a 90-day horizon, Roivant Sciences has a beta of 0.92 indicating Roivant Sciences market returns are correlated to returns on the market. As the market goes up or down, Roivant Sciences tends to follow. Additionally, Roivant Sciences has an alpha of 0.1527, implying that it can generate a 0.1527 percent excess return over Dow Jones Industrial after adjusting for the inherent market risk (beta).
   Roivant Sciences Price Density   
       Price  

Predictive Modules for Roivant Sciences

A variety of analytical techniques are available for forecasting Roivant Sciences and the broader stock market. From technical pattern analysis to statistical models, each method contributes a different perspective on Roivant Sciences. A systematic comparison of model outputs provides context to form a more balanced perspective on Roivant Sciences. Refining forecasting methods over time can incrementally improve the quality of decisions made about Roivant Sciences.
The mean reversion principle applied to Roivant Sciences' suggests that neither prolonged outperformance nor underperformance is permanent. Identifying the root cause of Roivant Sciences' price dislocation is essential before acting on a mean reversion signal. The mean reversion tendency in Roivant Sciences' price is a well-documented phenomenon in academic research. In many cases, Roivant Sciences' price extremes present statistical patterns that have recurred historically.
Sentiment
Range
LowSentimentHigh
26.1028.2830.46
Details
Intrinsic
Valuation
LowIntrinsicHigh
27.1529.3331.51
Details
Naive
Forecast
LowNextHigh
25.1827.3729.55
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
27.1828.4729.76
Details
Competitive analysis for Roivant Sciences compares its financial performance and valuation metrics against sector peers. Cross-sectional comparison separates idiosyncratic performance from sector-level dynamics. Roivant Sciences' metrics are most informative when compared against the strongest and weakest performers in its sector. Cross-company comparison helps validate or challenge assumptions embedded in Roivant Sciences' current valuation.

Primary Risk Indicators

The past 10-20 years have brought considerable volatility to the stock market, with Roivant Sciences experiencing notable price swings. Roivant Sciences has reflected this volatile environment with periods of significant price swings. Tracking shifts in Roivant Sciences' fundamental risk indicators is one approach to mitigating this exposure. This risk data equips investors with the information needed to adjust Roivant Sciences exposure proactively.
α
Alpha over Dow Jones
0.15
β
Beta against Dow Jones0.92
σ
Overall volatility
0.90
Ir
Information ratio 0.07

Investor Alerts and Insights

Alerts and suggestions for Roivant Sciences give investors a structured way to monitor the stock for material events. Roivant Sciences alerts cover shifts in fundamentals, technical conditions, and significant market-moving events. Alert frequency for Roivant Sciences adjusts dynamically based on market volatility and event activity. Regularly reviewing Roivant Sciences alerts keeps investors aligned with evolving market conditions.
Roivant Sciences has high likelihood to experience some financial distress in the next 2 years
ROIV reported previous year's revenue of $29.05 million. Net Loss for the year was -$356.73 million with loss before overhead, payroll, taxes, and interest of -$614.67 million.
Roivant Sciences currently holds about $1.94 billion in cash as of latest reporting with -$839.45 million of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.76.
Roughly 23.0% of ROIV outstanding shares are owned by corporate insiders

Price Density Drivers

Price behavior in Roivant Sciences reflects the combined effect of buyer and seller positioning dynamics and market sentiment. Reviewing the indicators below provides context for understanding the current drivers of Roivant Sciences price. Price density analysis for Roivant Sciences focuses on the forces that drive short-term price movements. Use the table below as a reference for tracking Roivant Sciences's key price density drivers over time.
Common Stock Shares Outstanding725.4 million
Cash And Short Term Investments4.89 billion

Roivant Sciences Fundamentals Growth

Roivant Sciences Stock performance is fundamentally tied to Roivant Sciences' financial health and growth outlook. Investors track revenue and earnings growth, margin stability, and balance sheet health for Roivant Sciences Stock. The market prices Roivant Sciences Stock according to Roivant Sciences' ability to generate revenue and manage debt effectively. Investors evaluating Roivant Sciences Stock should focus on Roivant Sciences' earnings quality and revenue momentum.

Performance Metrics & Calculation Methodology

Return quality for Roivant Sciences evaluates how consistent and repeatable performance has been across periods. Return persistence over multiple periods suggests a stable underlying driver rather than one-off outcomes. Roivant Sciences shows ROE of -19.14%, ROA of -14.47% (TTM).

Roivant Sciences values are built from periodic company reporting and market reference feeds, with reporting definitions aligned before display. Return and risk statistics are calculated from historical price series.

Editorial review and methodology oversight provided by: Michael Smolkin, Member of Macroaxis Board of Directors